<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580121</url>
  </required_header>
  <id_info>
    <org_study_id>WP42004</org_study_id>
    <secondary_id>2020-000216-30</secondary_id>
    <nct_id>NCT04580121</nct_id>
  </id_info>
  <brief_title>A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.</brief_title>
  <official_title>An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, entry-into-human (EIH) study will evaluate the safety, tolerability,&#xD;
      pharmacokinetics (PK), and pharmacodynamics of RO7283420. Escalating doses of RO7283420 will&#xD;
      be administered to participants with Acute Myeloid Leukemia (AML) in order to determine the&#xD;
      maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include AML participants with measurable disease, for whom standard-of-care&#xD;
      (SOC) is not available. Two Groups of AML participants will be included in this study:&#xD;
&#xD;
        -  Group I participants will have hematologic relapse/refractory disease (participants not&#xD;
           in CR or CRi i.e. with &gt;=5% blast cells in the bone marrow (BM) or presence of&#xD;
           circulating blast)&#xD;
&#xD;
        -  Group II participants will have molecular relapse/persistent disease (participants with&#xD;
           a CR or CRi, and a positive MRD based on local multi-parameter flow cytometry (MFC) or&#xD;
           molecular assessment).&#xD;
&#xD;
      The study consists of three parts:&#xD;
&#xD;
        -  Part A (single-participant dose escalation cohorts) - single participants from Group I&#xD;
           will receive increment-based escalating doses until a Grade &gt;=2 AE related to RO7283420&#xD;
           or a clear pharmacodynamic effect&#xD;
&#xD;
        -  Part B (multiple-participant dose escalation cohorts) - multiple-participant cohorts of&#xD;
           &gt;=3 participants will be enrolled for dose escalation for Group I and Group II&#xD;
           independently.&#xD;
&#xD;
        -  Part C (dose expansion) - participants will receive the respective identified RP2D for&#xD;
           that group.&#xD;
&#xD;
      Each participant will receive up to 6 cycles of treatment with RO7283420. At the end of cycle&#xD;
      6, only participants achieving at least partial remission may receive three additional&#xD;
      treatment cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2020</start_date>
  <completion_date type="Anticipated">October 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 18, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>From baseline up to 9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>From baseline up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Reduction (%) from Baseline in Blast Count in Peripheral Blood and/or Bone Marrow</measure>
    <time_frame>From baseline up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with &gt;= 50% Reduction from Baseline in Blast Count in Peripheral Blood and/or Bone Marrow</measure>
    <time_frame>From baseline up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of MRD (Measurable Residual Disease) Negative Participants over time According to Local MRD Assessment</measure>
    <time_frame>From baseline up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of RO7283420</measure>
    <time_frame>Day 1, 2, 3, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 of Cycle 2-9, at end of treatment visit (28 days after the last dose of RO7283420)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of RO7283420</measure>
    <time_frame>Day 1, 2, 3, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 of Cycle 2-9, at end of treatment visit (28 days after the last dose of RO7283420)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Concentration (Cmin) of RO7283420</measure>
    <time_frame>Day 1, 2, 3, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 of Cycle 2-9, at end of treatment visit (28 days after the last dose of RO7283420)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (Cl) of RO7283420</measure>
    <time_frame>Day 1, 2, 3, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 of Cycle 2-9, at end of treatment visit (28 days after the last dose of RO7283420)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume (V) of RO7283420</measure>
    <time_frame>Day 1, 2, 3, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 of Cycle 2-9, at end of treatment visit (28 days after the last dose of RO7283420)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) of RO7283420</measure>
    <time_frame>Day 1, 2, 3, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 of Cycle 2-9, at end of treatment visit (28 days after the last dose of RO7283420)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Titer of Anti-drug Antibodies (ADA) against RO7283420</measure>
    <time_frame>Day 1, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 and 8 of Cycle 2, Day 1 of Cycle 3-9, at end of treatment visit (28 days after the last dose of RO7283420)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>RO7283420 Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Group I will receive escalating doses of RO7283420, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1) for up to 6 cycles with a starting dose of 0.15mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7283420 Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple-participant cohorts of &gt;= 3 participants will be enrolled for dose escalation for Group I and Group II independently. Participants will be administered a starting dose of 0.15 mg or highest dose administered in Part A of RO7283420 once Q3W starting on C1D1 up to Cycle 6 to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). If needed, a step-up dosing regimen with more frequent administrations of RO7283420 during cycle 1 will be evaluated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7283420 Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the respective RP2D for Group I and Group II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7283420</intervention_name>
    <description>RO7283420 will be administered to participants by intravenous (IV) infusion or subcutaneous (SC) injection Q3W at a starting dose of 0.15mg.</description>
    <arm_group_label>RO7283420 Part A</arm_group_label>
    <arm_group_label>RO7283420 Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7283420</intervention_name>
    <description>RO7283420 at RP2D will be administered by IV infusion or SC injection as per dosing schedule determined in Part B.</description>
    <arm_group_label>RO7283420 Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab will be administered as an IV infusion 8 mg/kg (for participants with a weight of 30 kg and above) and 12 mg/kg (for participants with a weight of less than 30 kg). Tocilizumab will be given as rescue medication.</description>
    <arm_group_label>RO7283420 Part A</arm_group_label>
    <arm_group_label>RO7283420 Part B</arm_group_label>
    <arm_group_label>RO7283420 Part C</arm_group_label>
    <other_name>Actemra, RoActemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib 100 mg film-coated tablets will be administered daily until symptom resolution (up to 100 mg twice daily [BID] for a maximum 3 days); orally. Dasatinib will be given as rescue medication.</description>
    <arm_group_label>RO7283420 Part A</arm_group_label>
    <arm_group_label>RO7283420 Part B</arm_group_label>
    <arm_group_label>RO7283420 Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20 mg IV of dexamethasone will be administered as pre-medication at least 60 minutes prior to the all RO7283420 infusions or injections during cycle 1.</description>
    <arm_group_label>RO7283420 Part A</arm_group_label>
    <arm_group_label>RO7283420 Part B</arm_group_label>
    <arm_group_label>RO7283420 Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol/acetaminophen</intervention_name>
    <description>500 or 1000 mg of paracetamol/acetaminophen will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.</description>
    <arm_group_label>RO7283420 Part A</arm_group_label>
    <arm_group_label>RO7283420 Part B</arm_group_label>
    <arm_group_label>RO7283420 Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>25 mg or 50 mg of diphenhydramine will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.</description>
    <arm_group_label>RO7283420 Part A</arm_group_label>
    <arm_group_label>RO7283420 Part B</arm_group_label>
    <arm_group_label>RO7283420 Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  With confirmed diagnosis of primary or secondary AML according to WHO classification&#xD;
             2016, with measurable disease. Eligible participants need to have received&#xD;
             standard-of-care (SOC) and have no other SOC options available Participants who are&#xD;
             not willing to receive SOC will be not eligible. Two groups of participants (Group I -&#xD;
             hematologic relapsed/refractory and Group II - molecular relapsed/refractory) will be&#xD;
             included&#xD;
&#xD;
          -  Participants who have received hematopoietic stem cell transplant (HSCT) must have the&#xD;
             HSCT performed ≥ 90 days prior to the first dose of RO7283420 on Cycle 1 Day 1, having&#xD;
             demonstrated hematological engraftment and do not have an active Graft versus Host&#xD;
             Disease, not requiring immunosuppressive treatment (including but not limited to&#xD;
             cyclosporine, tacrolimus, sirolimus, and mycophenolate), which must be stopped at&#xD;
             least 28 days prior to the first dose of RO7283420 on Cycle 1 Day 1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Peripheral blast counts =&lt; 20,000/mm3 on Cycle 1 Day 1 prior to the first dosing&#xD;
&#xD;
          -  Confirmed genotype of HLA-A*02&#xD;
&#xD;
          -  Adequate renal (a creatinine clearance of &gt;=50 mL/min as calculated according to the&#xD;
             Cockroft-Gault formula) and adequate liver test results&#xD;
&#xD;
          -  Male or female participants agree to use contraception and the abstinence requirements&#xD;
             to prevent exposure of an embryo to the study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia (APL)&#xD;
&#xD;
          -  Core Binding Factor (CBF)-AML Note: participants with r/r CBF-AML after at least 2&#xD;
             salvage attempts can be enrolled into the study&#xD;
&#xD;
          -  Group II only: participants with normal karyotype and a favorable molecular profile&#xD;
             according to ELN guideline 2017&#xD;
&#xD;
          -  Participants with active bacterial, fungal or viral infection considered by the&#xD;
             Investigator to be clinically uncontrolled or of unacceptable risk upon the induction&#xD;
             of neutropenia (i.e. participants who are or should be on antimicrobial agents for the&#xD;
             treatment of active infection)&#xD;
&#xD;
          -  Grade &gt;= 2 glomerular proteinuria at screening or on Cycle 1 Day 1 prior to the first&#xD;
             dosing.&#xD;
&#xD;
          -  Another primary malignancy (other than AML) that requires active therapy. Adjuvant&#xD;
             hormonal therapy is allowed&#xD;
&#xD;
          -  Clinical evidence or history of central nervous system (CNS) leukemia&#xD;
&#xD;
          -  Presence of extramedullary disease at screening&#xD;
&#xD;
          -  Current or past history of CNS disease, such as stroke, CNS inflammation, epilepsy,&#xD;
             CNS vasculitis, or neurodegenerative disease&#xD;
&#xD;
          -  Participants who have a history of clinically significant liver disease, including&#xD;
             liver cirrhosis (e.g. Child-Pugh class B and C) or participants who have a history of&#xD;
             active or chronic infectious hepatitis unless serology demonstrates clearance of&#xD;
             infection&#xD;
&#xD;
          -  Participants who might refuse to receive blood products and/or have known&#xD;
             hypersensitivity to any of the components of RO7283420, tocilizumab, or dasatinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: WP42004 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre; Medical Oncology</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet; Hæmatologisk Klinik</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes; Departement D' Onco-Hematologie</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST PAPA GIOVANNI XXIII; Ematologia</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara; Unita Operativa Di Ematologia</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catala d´Oncologia Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial; Servicio de Hematología y Oncología</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. 12 de Octubre; Servicio de Hematologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe; Servicio de Hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital; Oncology and Hematology</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital; Oncology</name>
      <address>
        <city>Tainan</city>
        <zip>00704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan Universtiy Hospital; Division of Hematology</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

